Ocrevus is a intravenous treatment for both primary progressive and relapsing forms of multiple sclerosis. The approval is a major breakthrough since no treatments had previously been approved for primary progressive multiple sclerosis. This monoclonal antibody treatment works by
Ocrevus is a intravenous treatment for both primary progressive and relapsing forms of multiple sclerosis. The approval is a major breakthrough since no treatments had previously been approved for primary progressive multiple sclerosis. This monoclonal antibody treatment works by depleted B cells, a type of immune cell. Ocrevus is given intravenously with half given the first day and a second half given 2 weeks later, followed by a single infusion every 6 months.
I